2010-03-19 14:34:07 -

The Annual General Meeting of Tripep AB (STO:TPEP), held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the company’s business, i.e. to develop therapies for chronic diseases. As from Wednesday March 24, 2010, the company’s share will be traded under the code CTEC on First North.

Tripep develops the therapeutic DNA-vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B-virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. Tripep has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. Tripep also have part ownership

in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The Tripep share is admitted to trade on First North.
Remium AB is Certified Adviser for Tripep AB. For more information, please visit: www.tripep.se : In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

This information was brought to you by Cision www.cisionwire.com :



Tripep ABAnders Vahlne, CEO and Head of ResearchTel: +46 8

5858 1313mobile phone: +46 709 28 05 28E-mail: anders.vahlne@ki.se : mailto:anders.vahlne@ki.se